Quick Answer
LEXICON PHARMACEUTICALS, INC. reported Research And Development Expense of $61.12 million for the year ending 2025.
- LEXICON PHARMACEUTICALS, INC. showed a decrease of -27.7% in Research And Development Expense from 2024 to 2025.
- This data is from LEXICON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), LEXICON PHARMACEUTICALS, INC.'s Research And Development Expense has declined by 24.8%.
- Historical annual values: Fiscal year 2025: $61.12 million | Fiscal year 2024: $84.48 million | Fiscal year 2023: $58.89 million | Fiscal year 2022: $52.82 million | Fiscal year 2021: $55.05 million | Fiscal year 2020: $153.62 million | Fiscal year 2019: $91.92 million | Fiscal year 2018: $100.24 million | Fiscal year 2017: $152.22 million | Fiscal year 2016: $163.97 million | Fiscal year 2015: $95.19 million | Fiscal year 2014: $89.28 million | Fiscal year 2013: $89.68 million | Fiscal year 2012: $82.57 million | Fiscal year 2011: $91.83 million | Fiscal year 2010: $78.52 million | Fiscal year 2009: $81.24 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: